J Tolar

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. Tolar J, Park I, Xia L, Lees C, Peacock B, Webber B, et al. Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood. 2011;117:839-47 pubmed publisher
  2. Webber B, Tolar J. From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa. Mol Ther. 2015;23:987-992 pubmed publisher
  3. Lee C, Seo H, Armien A, Bates F, Tolar J, Azarin S. Modeling and rescue of defective blood-brain barrier function of induced brain microvascular endothelial cells from childhood cerebral adrenoleukodystrophy patients. Fluids Barriers CNS. 2018;15:9 pubmed publisher
  4. Tolar J, Xia L, Riddle M, Lees C, Eide C, McElmurry R, et al. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2011;131:848-56 pubmed publisher
    ..These data identify the potential of RDEB iPS cells to generate autologous hematopoietic grafts and skin cells with the inherent capacity to treat skin and mucosal erosions that typify this genodermatosis. ..
  5. Tolar J, Adair J, Antoniou M, Bartholomae C, Becker P, Blazar B, et al. Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting. Mol Ther. 2011;19:1193-8 pubmed publisher
    ..The report summarizes the roadmap for the development of gene therapy for FA. ..
  6. Poynter J, Bestrashniy J, Silverstein K, Hooten A, Lees C, Ross J, et al. Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology. BMC Cancer. 2015;15:769 pubmed publisher
    ..Targeted therapies, based on integrated analyses of molecular tumor data such as that presented here, may provide a way to secure high cure rates while reducing unintended health consequences. ..
  7. Tolar J, McGrath J, Xia L, Riddle M, Lees C, Eide C, et al. Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2014;134:1246-1254 pubmed publisher
    ..We believe this approach should be the starting point for autologous cellular therapies using 'natural' gene therapy in RDEB and other diseases. ..
  8. Nevala Plagemann C, Lee C, Tolar J. Placenta-based therapies for the treatment of epidermolysis bullosa. Cytotherapy. 2015;17:786-95 pubmed publisher
    ..In this Review, we will discuss how recent advances in placenta-based, umbilical cord blood-based and amniotic membrane-based therapies may play a role in the both the current and future treatment of RDEB. ..
  9. Ghosh A, Miller W, Orchard P, Jones S, Mercer J, Church H, et al. Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10 year combined experience of 2 centres. Mol Genet Metab. 2016;117:373-7 pubmed publisher
    ..In several individuals with decreased cardiac contractility, an improvement of their condition during enzyme replacement therapy enabled them to undergo transplantation, with one individual receiving full intensity conditioning. ..

More Information

Publications20

  1. Tolarová M, McGrath J, Tolar J. Venturing into the New Science of Nucleases. J Invest Dermatol. 2016;136:742-5 pubmed publisher
    ..Recent studies have shown that COL7A1 mutations in cells of patients with recessive dystrophic epidermolysis bullosa can be corrected by homology-directed DNA repair. ..
  2. Osborn M, Belanto J, Tolar J, Voytas D. Gene editing and its application for hematological diseases. Int J Hematol. 2016;104:18-28 pubmed publisher
  3. Yoon D, Osborn M, Tolar J, Kim C. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. Int J Mol Sci. 2018;19: pubmed publisher
    ..The impact of this approach on hematological malignancies is in its infancy, and in this review we discuss CAR-T cells and their synergy with immune-checkpoint blockade. ..
  4. Osborn M, Lees C, McElroy A, Merkel S, Eide C, Mathews W, et al. CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. Int J Mol Sci. 2018;19: pubmed publisher
    ..We predict that this design concept will be highly transferrable to most genes in multiple model systems representing a facile cellular engineering platform for promoting gene expression. ..
  5. Tolar J, Blazar B, Wagner J. Concise review: Transplantation of human hematopoietic cells for extracellular matrix protein deficiency in epidermolysis bullosa. Stem Cells. 2011;29:900-6 pubmed publisher
    ..Further modifications in the use of stem cell transplantation as a durable source of extracellular matrix proteins may make this regenerative medicine approach effective in other cutaneous and extracutaneous conditions. ..
  6. Tolar J, Ishida Yamamoto A, Riddle M, McElmurry R, Osborn M, Xia L, et al. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood. 2009;113:1167-74 pubmed publisher
  7. Vanden Oever M, Muldoon D, Mathews W, McElmurry R, Tolar J. miR-29 Regulates Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa. J Invest Dermatol. 2016;136:2013-2021 pubmed publisher
    ..Collectively, we identify miR-29 as an important factor in both regulating COL7A1 and inhibiting transforming growth factor-?-mediated fibrosis. ..
  8. Tolar J, Deeg H, Arai S, Horwitz M, Antin J, McCarty J, et al. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant. 2012;18:1007-11 pubmed publisher
    ..CY dose levels 50 and 100 mg/kg remain open. Thus, CY at doses of 150 mg/kg in combination with total body irradiation (2 Gy), fludarabine (120 mg/m(2)), and antithymocyte globulin was associated with excessive organ toxicity. ..
  9. Tolar J, O Shaughnessy M, Panoskaltsis Mortari A, McElmurry R, Bell S, Riddle M, et al. Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. Blood. 2006;107:4182-8 pubmed
    ..Our data indicate that the biodistribution and persistence of reporter gene-labeled MAPCs are maximized after intra-arterial delivery or host irradiation and that T cells, B cells, and NK cells contribute to in vivo MAPC rejection. ..
  10. Skvarova Kramarzova K, Osborn M, Webber B, Defeo A, McElroy A, Kim C, et al. CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. Int J Mol Sci. 2017;18: pubmed publisher
    ..Altogether we show the ability to correct a patient mutation in primary FANCD1 cells in a precise manner. These proof of principle studies support expanded application of gene editing for FA. ..
  11. request reprint
    Tolar J, Wang X, Braunlin E, McElmurry R, Nakamura Y, Bell S, et al. The host immune response is essential for the beneficial effect of adult stem cells after myocardial ischemia. Exp Hematol. 2007;35:682-90 pubmed